Immutep to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Immutep (ASX: IMM; NASDAQ: IMMP), a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced its participation in three major upcoming investor conferences.
The company will attend the Jones Healthcare and Technology Innovation Conference in Las Vegas on April 9, 2025, at 4:30 pm ET, followed by the Citizens Life Sciences Conference in New York on May 8, 2025, at 1:00 pm ET. Additionally, Immutep will participate in the Jefferies Global Healthcare Conference in New York on June 4-5, 2025, with detailed presentation information to be released later on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IMMP declined 5.65%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:
| Jones Healthcare and Technology Innovation Conference | ||
| Location: | Las Vegas, NV | |
| Date: | Wednesday, 9 April 2025 | |
| Time: | 4:30 pm ET | |
| The Citizens Life Sciences Conference | ||
| Location: | New York, NY | |
| Date: | Thursday, 8 May 2025 | |
| Time: | 1:00 pm ET | |
| Jefferies Global Healthcare Conference | ||
| Location: | New York, NY | |
| Date: | Wednesday & Thursday, 4 & 5 June 2025 | |
Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ
What investor conferences will Immutep (IMMP) attend in 2025?
When and where is Immutep (IMMP) presenting at the Jones Healthcare Conference?
What is the schedule for Immutep's (IMMP) presentation at the Citizens Life Sciences Conference?
Where can investors find information about Immutep's (IMMP) presentation at the Jefferies Conference?
